NanoBio® Corporation is a privately held biopharmaceutical company focused on developing and commercializing intranasal and intramuscular vaccines, based on our patented NanoStatTM vaccine adjuvant platform.
NanoBio Corporation was founded in 2000 as a spin-off from the Center for Biologic Nanotechnology at the University of Michigan. NanoBio’s lead product candidates include vaccines for RSV, seasonal and pandemic influenza, pertussis, anthrax, and HSV2. NanoBio’s patented NanoStat technology platform utilizes a novel oil-in-water emulsion adjuvant to enable vaccines that elicit broad protection against disease. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.